Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
brain metastases
immunotherapy
nivolumab
non-small cell lung cancer
poor performance status
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Mar 2021
02 Mar 2021
Historique:
received:
04
02
2021
revised:
23
02
2021
accepted:
24
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Anti-PD-1 antibodies prolong survival of performance status (PS) 0-1 advanced non-small-cell lung cancer (aNSCLC) patients. Their efficacy in PS 3-4 patients is unknown. Conse- cutive PS 3-4 aNSCLC patients receiving compassionate nivolumab were accrued by 12 French thoracic oncology departments, over 24 months. Overall survival (OS) was calculated using the Kaplan-Meier method. Prognostic variables were assessed using Cox proportional hazards models. Overall, 35 PS 3-4 aNSCLC patients (median age 65 years) received a median of 4 nivolumab infusions (interquartile range [IQR], 1-7) as first- (
Identifiants
pubmed: 33801285
pii: cancers13051040
doi: 10.3390/cancers13051040
pmc: PMC7958129
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2005 Apr 1;23(10):2136-44
pubmed: 15713598
J Clin Oncol. 2009 Mar 20;27(9):1394-400
pubmed: 19224850
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
J Thorac Oncol. 2019 Sep;14(9):e193-e195
pubmed: 31445732
J Thorac Oncol. 2019 Sep;14(9):1628-1639
pubmed: 31121324
Clin Lung Cancer. 2019 May;20(3):201-207
pubmed: 30442524
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Eur J Cancer. 2020 Mar;127:160-172
pubmed: 32028209
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Cancer Discov. 2020 Sep;10(9):1330-1351
pubmed: 32434947
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Thorac Oncol. 2007 Mar;2(3):230-6
pubmed: 17410046
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751414
Lung Cancer. 2008 Jul;61(1):61-6
pubmed: 18201795
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Ann Oncol. 2016 Jul;27(7):1354-6
pubmed: 27037297
Lancet Respir Med. 2020 Sep;8(9):895-904
pubmed: 32199466
Oncologist. 2020 Apr;25(4):306-e618
pubmed: 32297438
J Thorac Oncol. 2008 Feb;3(2):125-9
pubmed: 18303431
Lung Cancer. 2013 Jul;81(1):32-8
pubmed: 23541463
Lung Cancer. 2012 Sep;77(3):545-9
pubmed: 22633939
J Thorac Oncol. 2008 May;3(5):457-66
pubmed: 18448996
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Oncol. 2010 Jun;21(6):1290-1295
pubmed: 19914959
Am J Hosp Palliat Care. 2020 Mar;37(3):179-184
pubmed: 31307205
Lung Cancer. 2010 Dec;70(3):301-7
pubmed: 20400201
Cancer. 2020 May 15;126(10):2288-2295
pubmed: 32142165
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Cell Rep Med. 2020 Oct 20;1(7):100127
pubmed: 33205076
Ann Pathol. 2018 Apr;38(2):110-125
pubmed: 29571563
J Thorac Oncol. 2017 Jul;12(7):1161-1166
pubmed: 28238961